Research Analysts Offer Predictions for ARQT Q1 Earnings

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) – Research analysts at HC Wainwright decreased their Q1 2026 EPS estimates for shares of Arcutis Biotherapeutics in a research note issued on Thursday, February 26th. HC Wainwright analyst D. Tsao now anticipates that the company will earn ($0.08) per share for the quarter, down from their previous estimate of ($0.02). HC Wainwright currently has a “Buy” rating and a $34.00 target price on the stock. The consensus estimate for Arcutis Biotherapeutics’ current full-year earnings is ($1.33) per share. HC Wainwright also issued estimates for Arcutis Biotherapeutics’ FY2026 earnings at $0.18 EPS, FY2027 earnings at $0.83 EPS, FY2028 earnings at $1.45 EPS and FY2029 earnings at $1.91 EPS.

ARQT has been the topic of several other research reports. Mizuho increased their target price on Arcutis Biotherapeutics from $32.00 to $37.00 and gave the stock an “outperform” rating in a research note on Friday, November 28th. TD Cowen increased their price target on shares of Arcutis Biotherapeutics from $30.00 to $35.00 and gave the stock a “buy” rating in a research report on Thursday. Wall Street Zen lowered shares of Arcutis Biotherapeutics from a “strong-buy” rating to a “buy” rating in a research note on Saturday, February 14th. Zacks Research cut shares of Arcutis Biotherapeutics from a “strong-buy” rating to a “hold” rating in a report on Monday, December 29th. Finally, Needham & Company LLC upped their target price on shares of Arcutis Biotherapeutics from $31.00 to $36.00 and gave the stock a “buy” rating in a research note on Thursday. Six analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $32.14.

Arcutis Biotherapeutics Trading Down 5.6%

ARQT opened at $26.97 on Monday. Arcutis Biotherapeutics has a 52 week low of $11.86 and a 52 week high of $31.77. The company has a quick ratio of 2.99, a current ratio of 3.17 and a debt-to-equity ratio of 0.57. The business has a fifty day simple moving average of $27.24 and a 200-day simple moving average of $23.92. The firm has a market cap of $3.35 billion, a P/E ratio of -192.63 and a beta of 1.66.

Arcutis Biotherapeutics (NASDAQ:ARQT) last announced its earnings results on Wednesday, February 25th. The company reported $0.13 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.03 by $0.10. Arcutis Biotherapeutics had a negative return on equity of 10.26% and a negative net margin of 4.29%.The company had revenue of $129.50 million for the quarter, compared to analyst estimates of $110.79 million.

Institutional Investors Weigh In On Arcutis Biotherapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Sit Investment Associates Inc. acquired a new position in shares of Arcutis Biotherapeutics during the fourth quarter worth $376,000. Invesco Ltd. raised its stake in Arcutis Biotherapeutics by 59.3% in the fourth quarter. Invesco Ltd. now owns 307,382 shares of the company’s stock valued at $8,926,000 after buying an additional 114,430 shares in the last quarter. Mercer Global Advisors Inc. ADV purchased a new stake in Arcutis Biotherapeutics during the 4th quarter worth about $255,000. Mackenzie Financial Corp acquired a new position in shares of Arcutis Biotherapeutics during the 4th quarter worth about $1,374,000. Finally, NewEdge Advisors LLC increased its holdings in shares of Arcutis Biotherapeutics by 209.0% in the 4th quarter. NewEdge Advisors LLC now owns 1,545 shares of the company’s stock valued at $45,000 after acquiring an additional 1,045 shares during the last quarter.

Insiders Place Their Bets

In other news, Director Howard G. Welgus sold 10,000 shares of the business’s stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $25.05, for a total transaction of $250,500.00. Following the completion of the transaction, the director directly owned 59,744 shares of the company’s stock, valued at approximately $1,496,587.20. The trade was a 14.34% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Larry Todd Edwards sold 2,052 shares of the company’s stock in a transaction that occurred on Monday, February 2nd. The stock was sold at an average price of $25.50, for a total transaction of $52,326.00. Following the sale, the insider owned 148,865 shares in the company, valued at $3,796,057.50. The trade was a 1.36% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 112,999 shares of company stock worth $2,960,174. Corporate insiders own 9.40% of the company’s stock.

More Arcutis Biotherapeutics News

Here are the key news stories impacting Arcutis Biotherapeutics this week:

• Positive Sentiment: Solid Q4 results and revenue beat — Arcutis reported a robust Q4 with revenue growth and a GAAP EPS beat, driven by Zoryve adoption; the quarter and raised guidance underpin the bullish view on commercial execution. Arcutis Biotherapeutics surges on earnings beat, raised guidance
• Positive Sentiment: Multiple analyst price-target increases — Needham, TD Cowen and Guggenheim raised targets (to the mid-$30s) and maintain buy ratings, signaling analyst confidence in growth and creating upside narrative for the stock. Benzinga coverage of analyst price-target changes
• Positive Sentiment: Bull case coverage highlights pipeline and label-expansion catalysts — Recent analyst and media pieces emphasize Zoryve market leadership, operating leverage and upcoming pediatric/label catalysts that could support longer-term upside. Arcutis Earnings: Zoryve Dominance And Pipeline Catalysts Drive The Bull Case
• Neutral Sentiment: Investor presentation scheduled — Management will present at TD Cowen’s healthcare conference next week, giving investors an opportunity for updated guidance/visibility; this is a near-term catalyst but not an immediate earnings event. Arcutis Management to Present at TD Cowen’s 46th Annual Health Care Conference
• Neutral Sentiment: Broad coverage and transcripts available — Earnings call transcript and multiple recaps give investors transparency into execution and guidance; this helps short- and long-term assessment but is informational. Arcutis (ARQT) Q4 2025 Earnings Call Transcript
• Negative Sentiment: Near-term EPS cuts by HC Wainwright — Despite maintaining a Buy and $34 target, HC Wainwright lowered Q2–Q4 2026 EPS estimates, which can temper short-term sentiment and provide a rationale for profit-taking after the post-earnings rally.
• Negative Sentiment: Mixed/unclear short-interest data — Recent short-interest reports appear inconsistent (zero/NaN entries), creating uncertainty about downside pressure from traders; unclear short-covering dynamics can add volatility.

About Arcutis Biotherapeutics

Arcutis Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for immuno-inflammatory skin diseases. The company’s research and development efforts center on targeted treatments that address the underlying biology of conditions such as plaque psoriasis, atopic dermatitis, seborrheic dermatitis and vitiligo. Arcutis employs a precision-medicine approach to deliver topical therapies designed to improve efficacy and tolerability compared with existing treatment options.

In August 2022, Arcutis received U.S.